CG Oncology, Inc. (CGON)
62.22
+0.29
(+0.47%)
USD |
NASDAQ |
Oct 21, 16:00
62.22
0.00 (0.00%)
After-Hours: 16:51
CG Oncology Shareholders Equity (Quarterly) : 1.029B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.029B |
| March 31, 2026 | 1.092B |
| December 31, 2025 | 752.60M |
| September 30, 2025 | 687.64M |
| June 30, 2025 | 670.36M |
| March 31, 2025 | 704.76M |
| December 31, 2024 | 733.38M |
| September 30, 2024 | 536.77M |
| Date | Value |
|---|---|
| June 30, 2024 | 552.36M |
| March 31, 2024 | 568.94M |
| December 31, 2023 | 184.79M |
| September 30, 2023 | 199.87M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 125.18M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.086B |
| Total Liabilities (Quarterly) | 56.54M |
| Debt to Equity Ratio | 0.0086 |
| Current Ratio | 22.22 |
| Net Debt Paydown Yield | -0.02% |